文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

美国国立综合癌症网络(NCCN)指南见解:造血生长因子,2022年第1版

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.

作者信息

Griffiths Elizabeth A, Roy Vivek, Alwan Laura, Bachiashvili Kimo, Baird John, Cool Rita, Dinner Shira, Geyer Mark, Glaspy John, Gojo Ivana, Hicks Ashley, Kallam Avyakta, Kidwai Wajih Zaheer, Kloth Dwight D, Kraut Eric H, Landsburg Daniel, Lyman Gary H, Mahajan Anjlee, Miller Ryan, Nachar Victoria, Patel Seema, Patel Shiven, Perez Lia E, Poust Adam, Riaz Fauzia, Rosovsky Rachel, Rugo Hope S, Simon Shayna, Vasu Sumithira, Wadleigh Martha, Westbrook Kelly, Westervelt Peter, Berardi Ryan A, Pluchino Lenora

机构信息

Roswell Park Comprehensive Cancer Center.

Mayo Clinic Cancer Center.

出版信息

J Natl Compr Canc Netw. 2022 May;20(5):436-442. doi: 10.6004/jnccn.2022.0026.


DOI:10.6004/jnccn.2022.0026
PMID:35545171
Abstract

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

摘要

《NCCN造血生长因子指南》针对发热性中性粒细胞减少症(FN)、化疗引起的血小板减少症(CIT)以及化疗引起的贫血(CIA)的临床管理中生长因子的恰当使用给出了建议。对这些后遗症的管理和预防是许多接受癌症治疗患者支持性护理的重要组成部分。这些指南的目的是将非髓系恶性肿瘤成年患者中FN、CIT和CIA的评估、预防及治疗付诸实践,并使患者和临床医生能够根据个体患者的情况评估FN、CIT和CIA的管理方案。这些《NCCN指南见解》总结了《NCCN造血生长因子指南》近期的重要更新内容,特别强调了新纳入的关于CIT的章节。

相似文献

[1]
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.

J Natl Compr Canc Netw. 2022-5

[2]
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.

J Natl Compr Canc Netw. 2020-1

[3]
Cancer- and chemotherapy-induced anemia.

J Natl Compr Canc Netw. 2012-5

[4]
Current and future use of hematopoietic growth factors in cancer medicine.

Hematol Oncol. 2004-9

[5]
Managing hematologic toxicities.

J Support Oncol. 2004

[6]
Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions.

Curr Opin Oncol. 1991-8

[7]
[Hematopoietic growth factors in cancer management].

Duodecim. 1993

[8]
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2017-12

[9]
Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.

Oncol Nurs Forum. 2010-11

[10]
A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.

Curr Opin Hematol. 2011-1

引用本文的文献

[1]
The Role of Preventive Nursing Interventions in Reducing Treatment-Related Complications in Ovarian Cancer Patients: A Retrospective Cohort Study.

Int J Womens Health. 2025-7-17

[2]
Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.

Front Oncol. 2025-7-4

[3]
Diagnosis and management of neutropenia.

Blood Res. 2025-5-26

[4]
Chemotherapy-induced febrile neutropenia followed by acute hepatitis E virus infection in rectal cancer patient with synchronous liver and lung metastasis: a case report.

BMC Infect Dis. 2025-5-13

[5]
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.

BMC Cancer. 2025-3-17

[6]
Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment.

Br J Haematol. 2025-4

[7]
Cresp: transforming the landscape of chemotherapy-induced anemia - a comprehensive retrospective real-world analysis in 523 Indian patients.

Front Oncol. 2025-1-24

[8]
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.

Front Oncol. 2025-1-16

[9]
Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies.

Pediatr Blood Cancer. 2025-3

[10]
Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system.

BMJ Open. 2024-11-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索